trial

Metformin Treatment on Cognitive Impairment of Schizophrenia

NCTId NCT05838573
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 120 (actual)
Sponsored by Central South University
Primary completion 2026-06-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-05-08
Primary completion
2026-06-08
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Metformin treatmentBaseline assessmentsVolunteer assessments

Sponsors

Central South UniversityLead Sponsor
Shandong Mental Health CenterCollaborator
The Second People's Hospital of Dali Bai Autonomous PrefectureCollaborator
The Third people's Hospital of JiangyinCollaborator

Investigators

1
Renrong Wu, M.D., Ph.D.Study Chair

Sites

4 total
Changsha, ChinaJiangyin, ChinaJinan, ChinaDali, China

Linked catalysts

1
Metformin Treatment on Cognitive Impairment of Schizophrenia — primary completion2026-06-08

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE3
Primary Completion Date
2026-06-08
Status
COMPLETED
relationships
The graph out of here
drug
Metformin treatment
drug
Baseline assessments
drug
Volunteer assessments
drug
lead_sponsor
Central South University
company
collaborator
Shandong Mental Health Center
company
The Second People's Hospital of Dali Bai Autonomous Prefecture
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
investigator
Renrong Wu, M.D., Ph.D.
person